ad-cea vaccine
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2010 (NCT01147965)
Timeline
Indications
Mechanism of action
- Carcinoembryonic antigen-related cell adhesion molecule 5Immunity, active
CEACAM5 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ad5 cea vaccine
- ad-cea vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03050814 | Phase 2 | Apr 5, 2017 | National Cancer Institute (NCI) |
| NCT01147965 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2010 | Duke University, NantCell, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| NantCell, Inc. | For profit | 1 | 1 | 1 | 2010 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2017 |
3 organizations
Page 1 / 1